JRBrown Bio Consulting has over 28 years experience in providing impactful bioinformatics and computational biology support to biopharma R&D covering multiple therapeutic areas in a variety of organizations spanning large pharmaceutical companies (GSK), biotechs (i.e., Kaleido Biosciences, Novasenta). Our academic experience includes the USA (i.e., Drexel University, and University of Florida and Canada (McGIll University, Simon Fraser University and Dalhousie University).
Our core goal is to enable data-driven decision-making in the life sciences through innovative computational biology and data science solutions combined with an in-depth knowledge of biology and drug discovery. Consulting capabilities span the entire drug development pipeline from early target discovery and validation through all clinical phases to launched products, across the key business units — pharmaceuticals, vaccines and consumer heath. We are particularly experienced in the design, execution and analytics involved with multi-omics platforms for both pre-clinical and clinical research programs.
We have expertise in developing strategic drug discovery solutions using advanced data analytics to multidimensional datasets including human genetics, next generation sequencing (NGS – transcriptomics, single-cell genomics, whole genome sequencing [WGS]), microbial WGS, microbiome metagenomics, molecular evolution and host-pathogen interactions.
These capabilities are coupled with in-depth biological knowledge of diverse therapy areas including viral, bacterial and parasite infections, oncology and metabolic, respiratory, neuro-degenerative and autoimmune diseases. For example, we initiated and led diverse therapeutic discovery projects related to the gut, lung, urogenital and skin microbiome and overall human immune system-microbial interactions. We also support consulting projects across the broad biopharma sectors of pharmaceuticals, vaccines, consumer health, diagnostics and global health.
Additionally, with our extensive leadership experience in leading matrix teams of specialists in data science, biology, chemistry and clinical development we can help with designing and implementing a strategic vision for R&D organizations. We can support the build-out and management of in-house computational biology and data science teams and resources.
Also offered are customized deep-dive analyses, due diligences and strategic planning into specific disease areas, therapeutic opportunities, novel biopharma technologies, public and private partnerships and more.
Finally, we have an extensive public-facing scientific profile with 118 publications, many in top scientific journals. Thus another area of excellence is scientific communications.
Please feel free to contact us to discuss your consulting project needs — small or large!
Best regards,
James (Jim) Brown, Principal Consultant and Founder